title: Irisin is more strongly predicted by muscle oxidative potential than adiposity in non-diabetic men.
abstract: Numerous controversies surround the peptide hormone irisin. Although implicated as a myokine promoting the browning of adipose tissue in rodents, its roles in humans remain unclear. Contradictory results have also been found with respect to the relationships between adiposity or metabolic health and plasma irisin levels in humans. We investigated the relationship between irisin levels and body composition (hydrostatic weighing), insulin sensitivity (hyperinsulinemic-euglycemic clamp), fitness level (ergocycle VO2max) and skeletal muscle metabolic profile in 53 men (aged 34-53 years) from four groups: sedentary non-obese controls (body mass index [BMI] <25 kg/m(2)), sedentary obese (BMI >30 kg/m(2)), sedentary obese glucose-intolerant, and non-obese highly trained endurance active. Baseline plasma irisin levels were significantly different between groups, being lowest in trained men (140.6 ± 38.2 ng/mL) and highest in metabolically deteriorated glucose-intolerant subjects (204.0 ± 50.5 ng/mL; ANOVA p = 0.01). Including all subjects, irisin levels were positively associated with adiposity (e.g. fat mass, r = 0.430, p < 0.01) and negatively associated with fitness (r = -0.369, p < 0.01), insulin sensitivity (M/I, r = -0.355, p < 0.01) and muscle citrate synthase (CS) activity (r = -0.482, p < 0.01). Most correlations lost statistical significance when excluding active individuals, except for insulin resistance (r = -0.413, p < 0.01) and CS (r = -0.462, p < 0.01). Multiple regression analyses reveal CS as the strongest independent predictor of irisin levels (r(2) range 0.214 to 0.237). We conclude that muscle oxidative potential is an important factor linked to circulating irisin levels.
authors.affiliation: Department of Kinesiology, Université Laval, Québec, QC, Canada.
authors.forename: Claire
authors.initials: C
authors.lastname: Huth
authors.forename: Marie-Julie
authors.initials: MJ
authors.lastname: Dubois
authors.forename: André
authors.initials: A
authors.lastname: Marette
authors.forename: Angelo
authors.initials: A
authors.lastname: Tremblay
authors.forename: S John
authors.initials: SJ
authors.lastname: Weisnagel
authors.forename: Michel
authors.initials: M
authors.lastname: Lacaille
authors.forename: Pascale
authors.initials: P
authors.lastname: Mauriège
authors.forename: Denis R
authors.initials: DR
authors.lastname: Joanisse
mesh_terms: D050154:Adiposity; D000328:Adult; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D008931:Mitochondria, Muscle / Q000378:metabolism; D018482:Muscle, Skeletal / Q000378:metabolism*; D009765:Obesity / Q000097:blood* / Q000473:pathology; D010084:Oxidation-Reduction
chemical_list: C577593:FNDC5 protein, human; D005353:Fibronectins
references.citation: PLoS One. 2013 Apr 11;8(4):e60563
references.pmid: 23593248
references.citation: Peptides. 2014 Feb;52:68-73
references.pmid: 24345335
references.citation: Nature. 2012 Aug 30;488(7413):E9-10; discussion E10-1
references.pmid: 22932392
references.citation: Am J Physiol. 1997 Feb;272(2 Pt 1):E248-54
references.pmid: 9124331
references.citation: J Diabetes Complications. 2014 Mar-Apr;28(2):208-13
references.pmid: 24332937
references.citation: J Physiol. 2014 Mar 1;592(5):1091-107
references.pmid: 24297848
references.citation: Med Sci Sports Exerc. 1982;14(5):377-81
references.pmid: 7154893
references.citation: J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907
references.pmid: 24057291
references.citation: Nutr Res Pract. 2014 Apr;8(2):177-82
references.pmid: 24741402
references.citation: Int J Biol Sci. 2014 Mar 11;10 (3):338-49
references.pmid: 24644429
references.citation: Diabetes Metab. 2009 Nov;35(5):398-403
references.pmid: 19734081
references.citation: Cell. 2012 Jul 20;150(2):366-76
references.pmid: 22796012
references.citation: Am J Hum Biol. 2014 Mar-Apr;26(2):198-207
references.pmid: 24375850
references.citation: Obes Res. 1999 Nov;7(6):556-63
references.pmid: 10574514
references.citation: Med Sci Sports Exerc. 1995 May;27(5):721-9
references.pmid: 7674877
references.citation: Am J Physiol. 1988 Mar;254(3 Pt 1):E248-59
references.pmid: 3126668
references.citation: Peptides. 2014 Nov;61:130-6
references.pmid: 25261800
references.citation: Metabolism. 2012 Dec;61(12):1725-38
references.pmid: 23018146
references.citation: Peptides. 2013 Jan;39:125-30
references.pmid: 23219488
references.citation: Appl Physiol Nutr Metab. 2009 Apr;34(2):99-106
references.pmid: 19370039
references.citation: Neuroscience. 2013 Jun 14;240:155-62
references.pmid: 23470775
references.citation: Nature. 2012 Jan 11;481(7382):463-8
references.pmid: 22237023
references.citation: J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78
references.pmid: 23436919
references.citation: Adipocyte. 2013 Oct 1;2(4):289-93
references.pmid: 24052909
references.citation: Int J Endocrinol. 2014;2014:857270
references.pmid: 24864142
references.citation: Diabetes Obes Metab. 2014 Aug;16(8):711-8
references.pmid: 24476050
references.citation: Clin Endocrinol (Oxf). 2015 Apr;82(4):467-74
references.pmid: 25287317
references.citation: J Endocrinol. 2014 Jul;222(1):R25-38
references.pmid: 24781257
references.citation: J Biol Chem. 2013 Nov 22;288(47):33738-44
references.pmid: 24114836
references.citation: Circulation. 2001 Oct 2;104(14 ):1694-740
references.pmid: 11581152
references.citation: J Physiol Biochem. 2015 Sep;71(3):547-58
references.pmid: 25820474
references.citation: Int J Obes Relat Metab Disord. 2001 Aug;25(8):1144-53
references.pmid: 11477499
references.citation: Clin Physiol. 1986 Aug;6(4):347-56
references.pmid: 2943549
references.citation: Diabetes Care. 1999 May;22(5):684-91
references.pmid: 10332666
references.citation: Horm Metab Res. 2014 Jul;46(8):591-6
references.pmid: 24459033